Pharmacogenetic angiogenesis profiling for first-line chemotherapy in patients with advanced gastric cancer

Cancer Investigation

Volumn 31, Issue 6, 2013, Pages 390-396

  Dan, Su ^a   Bai, Li ^a   Li Jie, Wang ^a   Ting, Zhang ^a   Zhi Yuan, Mao ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Endostatin; Endothelial nitric oxide synthase; Single nucleotide polymorphism; Vascular endothelial growth factor

Indexed keywords

DOCETAXEL; ENDOSTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; OXALIPLATIN;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

ADENOCARCINOMA; ADULT; AGED; DISEASE-FREE SURVIVAL; ENDOSTATINS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84879490047     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.795580     Document Type: Article

References (38)

1. Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: Current management and new treatment developments. Drugs 2008;68:299-317 (Pubitemid 351227347)
2. Jiang Y,Ajani JA.Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 2010;26:640-646
3. Atsushi O. Chemotherapy for metastatic gastric cancer: Past, present, and future. J Gastroenterol 2008;43:256-264
4. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186
5. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934
6. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660 (Pubitemid 36749213)
7. Gerger A, Labonte M, Lenz HJ. Molecular predictors of response to antiangiogenesis therapies. Cancer J 2011;17:134-141
8. Wu LC, Zhang WD. Clinical trials of antiangiogenesis therapy on gastric cancer. Gastroen Res 2008;1:14-19
9. Yancopoule GD, Davis S, Gale, NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other disease. Nature 2000;407:249-257
11. Ferrara N. Vascular endothelial growth factor. Atheroscler Thromb Vasc Biol 2009;29:789-791
12. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001;2:667-673 (Pubitemid 33085812)
13. Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004;101:1364-1374 (Pubitemid 39180392)
14. MatteiMG, Borg JP, Rosnet O,Marme D, Birnbaum D. Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Genomics 1996;31:168-169 (Pubitemid 26076486)
15. Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 2000;12:1230-1235
16. Hansen TF, Spindler KL, Lorentzen KA,OlsenDA,Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A The importance of-460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. J Cancer Res Clin Oncol 2010;136:751-758
17. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010;21:21-26
18. Lose F, Nagle CM, O'Mara T, Batra J, Bolton KL, Song H, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Pharoah PD, Kedda MA, Spurdle AB. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol 2010;119:479-483
19. Wu X, Li D, Liu Z, Wan X, Wu Y, Quian Q. Vascular endothelial growth factor 1498C/T, 936C/T polymorphisms associated with increased risk of colorectal adenoma: A Chinese case-control study. Mol Biol Rep 2011;38:1949-1955
20. Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009;19:338-343
21. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-6741
22. TherasseP, ArbuckSG,EisenhauerEA,Wanders J,KaplanRS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, ChristianMC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
23. Lee PH, Shatkay H. F-SNP: Computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008;36:D820-D824 (Pubitemid 351149829)
24. Lee PH, Shatkay H. An integrative scoring system for ranking SNPs by their potential deleterious effects. Bioinformatics 2009;25:1048-1055
25. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 2000;471:45-50 (Pubitemid 30173290)
26. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2011;17:5783-5792
27. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25 (Pubitemid 27076453)
28. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab inmetastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14:22-28
29. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 2007;67:1407-1410 (Pubitemid 46383362)
30. Fukumura D, Kashiwagi, S, Jain, RK. The role of nitric oxide in tumor progression. Nat Rev Cancer 2006;6:521-534 (Pubitemid 43980541)
31. Choi JY, Lee KM, Noh DY, Ahn SH, Lee JE, Han W, Jang IJ, Shin SG, Yoo KY, Hayes RB, Kang D. Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 2006;100:213-218 (Pubitemid 44631923)
32. Funke S, Risch A, Nieters A, Hoffmeister M, Stegmaier C, Seiler CM, Brenner H, Chang-Claude J. Genetic polymorphisms in genes related to oxidative stress (GSTP1, GSTM1, GSTT1, CAT, MnSOD, MPO, eNOS) and survival of rectal cancer patients after radiotherapy. J Cancer Epidemiol 2009;2009: 302047-302052
33. Lei Y, Fang F, YangZ, YuL.The associationbetween twopolymorphisms of eNOS and breast cancer risk: A meta-Analysis. Breast Cancer Res Treat 2010;124:223-227
34. Kim YJ, Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kang BW, Park JY, Park JS, Choi GS. No association of the eNOS gene polymorphisms with survival in patients with colorectal cancer. Med Oncol 2011;28:1075-1079
35. Wang XL, Sim AS,Wang MX, Murrell GA, Trudinger B,Wang, J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 2000;471:45-50 (Pubitemid 30173290)
36. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285 (Pubitemid 28015876)
37. Iughetti P, Suzuki O, Godoi PH, Alves VA, Sertíe AL, Zorick T, Soares F, Camargo A, Moreira ES, di Loreto C, Moreira-Filho CA, Simpson A, Oliva G, Passos-Bueno MR. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001;61:7375-7378 (Pubitemid 32995018)
38. Lurje G, HusainH, PowerDG, Yang D, Groshen S, PohlA, Zhang W, Ning Y,Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz HJ. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol 2010;21:78-86